These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8961974)
1. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. Chen CL; Fuscoe JC; Liu Q; Pui CH; Mahmoud HH; Relling MV J Natl Cancer Inst; 1996 Dec; 88(24):1840-7. PubMed ID: 8961974 [TBL] [Abstract][Full Text] [Related]
2. A human lymphoid leukemia cell line with a V(D)J recombinase-mediated deletion of hprt. Chen CL; Woo MH; Neale GA; Goorha RM; Fuscoe JC; Behm FG; Mathew S; Relling MV Mutat Res; 1998 Jul; 403(1-2):113-25. PubMed ID: 9726012 [TBL] [Abstract][Full Text] [Related]
3. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Chen CL; Fuscoe JC; Liu Q; Relling MV Blood; 1996 Sep; 88(6):2210-8. PubMed ID: 8822941 [TBL] [Abstract][Full Text] [Related]
4. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Libura J; Slater DJ; Felix CA; Richardson C Blood; 2005 Mar; 105(5):2124-31. PubMed ID: 15528316 [TBL] [Abstract][Full Text] [Related]
5. MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells. Moneypenny CG; Shao J; Song Y; Gallagher EP Carcinogenesis; 2006 Apr; 27(4):874-81. PubMed ID: 16377807 [TBL] [Abstract][Full Text] [Related]
6. Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines. Liu WM; Oakley PR; Joel SP Leukemia; 2002 Sep; 16(9):1705-12. PubMed ID: 12200685 [TBL] [Abstract][Full Text] [Related]
7. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Liu WM; Joel SP Cancer Chemother Pharmacol; 2003 Apr; 51(4):291-6. PubMed ID: 12721756 [TBL] [Abstract][Full Text] [Related]
8. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy. Karnaoukhova L; Moffat J; Martins H; Glickman B Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103 [TBL] [Abstract][Full Text] [Related]
9. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. Kollmannsberger C; Beyer J; Droz JP; Harstrick A; Hartmann JT; Biron P; Fléchon A; Schöffski P; Kuczyk M; Schmoll HJ; Kanz L; Bokemeyer C J Clin Oncol; 1998 Oct; 16(10):3386-91. PubMed ID: 9779717 [TBL] [Abstract][Full Text] [Related]
10. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Kaufmann SH Cancer Res; 1989 Nov; 49(21):5870-8. PubMed ID: 2790800 [TBL] [Abstract][Full Text] [Related]
11. Etoposide-induced DNA cleavage in human leukemia cells. Edwards CM; Glisson BS; King CK; Smallwood-Kentro S; Ross WE Cancer Chemother Pharmacol; 1987; 20(2):162-8. PubMed ID: 2822274 [TBL] [Abstract][Full Text] [Related]
12. Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis. RamaChandran S; Ariffin H Pediatr Blood Cancer; 2009 Sep; 53(3):488-90. PubMed ID: 19434733 [TBL] [Abstract][Full Text] [Related]
13. [Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs]. Dassonneville L; Bailly C Bull Cancer; 1998 Mar; 85(3):254-61. PubMed ID: 9752316 [TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. Mistry AR; Felix CA; Whitmarsh RJ; Mason A; Reiter A; Cassinat B; Parry A; Walz C; Wiemels JL; Segal MR; Adès L; Blair IA; Osheroff N; Peniket AJ; Lafage-Pochitaloff M; Cross NC; Chomienne C; Solomon E; Fenaux P; Grimwade D N Engl J Med; 2005 Apr; 352(15):1529-38. PubMed ID: 15829534 [TBL] [Abstract][Full Text] [Related]
15. Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia. Hars ES; Lyu YL; Lin CP; Liu LF Cancer Res; 2006 Sep; 66(18):8975-9. PubMed ID: 16982737 [TBL] [Abstract][Full Text] [Related]
16. DNA damage induced by etoposide; a comparison of two different methods for determination of strand breaks in DNA. Walles SA; Zhou R; Liliemark E Cancer Lett; 1996 Aug; 105(2):153-9. PubMed ID: 8697438 [TBL] [Abstract][Full Text] [Related]
17. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? Dissing M; Le Beau MM; Pedersen-Bjergaard J J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906 [TBL] [Abstract][Full Text] [Related]
18. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Bowman KJ; Newell DR; Calvert AH; Curtin NJ Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322 [TBL] [Abstract][Full Text] [Related]
19. The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapy. Fuscoe JC; Knapp GW; Hanley NM; Setzer RW; Sandlund JT; Pui CH; Relling MV Mutat Res; 1998 Nov; 419(1-3):107-21. PubMed ID: 9804912 [TBL] [Abstract][Full Text] [Related]
20. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Pui CH; Relling MV; Behm FG; Hancock ML; Boyett JM; Raimondi SC; Krance RA; Mahmoud HH; Ribeiro RC; Sandlund JT Leukemia; 1995 Oct; 9(10):1680-4. PubMed ID: 7564509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]